8-K: SelectQuote Q2 FY26 Revenue Up, Guidance Lowered

SelectQuote, Inc. reported a 12% increase in consolidated revenue for the second quarter of fiscal year 2026, reaching $537.1 million, but revised its full-year guidance downwards due to partner-driven headwinds.

Summary

• Consolidated revenue for Q2 FY2026 increased by 11.6% year-over-year to $537.1 million.
• Net income for Q2 FY2026 rose by 30.3% to $69.3 million.
• Adjusted EBITDA for Q2 FY2026 slightly decreased by 3.2% to $84.7 million.
• Senior segment revenue grew 2% to $261.5 million, with approved Medicare Advantage policies up 4% to 257,279.
• Healthcare Services segment revenue surged 26% to $230.7 million, with SelectRx members increasing 17% to 113,483.
• Life segment revenue increased 9% to $43.6 million, driven by a 24% rise in Final Expense premiums.
• Revised fiscal year 2026 guidance for revenue is now $1.61 billion to $1.71 billion, down from $1.65 billion to $1.75 billion.
• Revised fiscal year 2026 guidance for Adjusted EBITDA is now $90 million to $100 million, down from $120 million to $150 million.
• Successfully refinanced term debt with a new $415 million credit facility, extending maturity to January 2031.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While Q2 operational performance, particularly in the Senior segment, showed resilience and revenue growth was solid, the significant downward revision of full-year guidance due to external headwinds introduces uncertainty and impacts profitability expectations.

Positives

• Consolidated revenue increased 11.6% year-over-year to $537.1 million in Q2 FY2026.
• Net income significantly improved by 30.3% year-over-year to $69.3 million in Q2 FY2026.
• Senior segment demonstrated strong operational execution with 2% revenue growth and 4% higher approved Medicare Advantage policies.
• Senior segment maintained strong Adjusted EBITDA margins of 39%.
• Healthcare Services segment showed robust revenue growth of 26% year-over-year to $230.7 million.
• SelectRx membership grew by 17% to 113,483 members.
• Life segment revenue increased 9%, with Final Expense premiums up 24%.
• Successful refinancing of term debt with a new $415 million credit facility, extending maturity to January 2031 and enhancing capital flexibility.
• High-touch model achieved a strong recapture rate of customers impacted by carrier policy cancellations during AEP.
• New multiyear agreement with a major PBM partner provides go-forward rate predictability for Healthcare Services.

Negatives

• Consolidated Adjusted EBITDA decreased by 3.2% year-over-year to $84.7 million in Q2 FY2026.
• Healthcare Services Adjusted EBITDA significantly declined by 62% year-over-year to $0.8 million, primarily due to PBM reimbursement rate pressure.
• Life segment Adjusted EBITDA decreased by 25% year-over-year to $5.6 million.
• Fiscal year 2026 revenue guidance was lowered from a range of $1.65 billion $1.75 billion to $1.61 billion $1.71 billion.
• Fiscal year 2026 Adjusted EBITDA guidance was lowered from a range of $120 million $150 million to $90 million $100 million.
• The revised guidance is attributed to partner-driven headwinds, specifically a national carrier curtailing MA policy volume and previously communicated PBM reimbursement changes.
• Lifetime Value of Commissions per Approved Medicare Advantage Policy decreased by 4% to $874.

Risks

• Reliance on a limited number of insurance carrier partners and potential termination of those relationships.
• Existing and future laws and regulations affecting the health insurance market.
• Changes in health insurance products offered by insurance carrier partners and the health insurance market generally.
• Insurance carriers offering products and services directly to consumers.
• Changes to commissions paid by insurance carriers and underwriting practices.
• Competition with brokers, online brokers, and carriers selling directly to consumers.
• Competition from government-run health insurance exchanges.
• Developments in the U.S. health insurance system.
• Dependence on revenue from the senior segment and downturns in senior health, life, automotive, and home insurance industries.
• Ability to develop new offerings and penetrate new vertical markets.
• Risks from third-party products.
• Failure to enroll individuals during the Medicare annual enrollment period.
• Ability to attract, integrate, and retain qualified personnel.
• Dependence on lead providers and ability to compete for leads.
• Failure to obtain and/or convert sales leads to actual sales of insurance policies.
• Access to data from consumers and insurance carriers.
• Accuracy of information provided from and to consumers during the insurance shopping process.
• Cost-effective advertisement through internet search engines.
• Ability to contact consumers and market products by telephone.
• Global economic conditions, including inflation.
• Disruption to operations as a result of future acquisitions.
• Significant estimates and assumptions in the preparation of financial statements.
• Impairment of goodwill.
• Potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act.
• Existing and future indebtedness and ability to maintain compliance with debt covenants.
• Access to additional capital.
• Failure to protect intellectual property and brand.
• Fluctuations in financial results caused by seasonality.
• Accuracy and timeliness of commissions reports from insurance carriers.
• Timing of insurance carriers' approval and payment practices.
• Factors that impact the estimate of the constrained lifetime value of commissions per policyholder.
• Changes in accounting rules, tax legislation, and other legislation.
• Disruptions or failures of technological infrastructure and platform.
• Failure to maintain relationships with third-party service providers.
• Cybersecurity breaches or other attacks involving systems or those of partners/providers.
• Ability to protect consumer information and other data.
• Failure to market and sell Medicare plans effectively or in compliance with laws.
• Factors related to the pharmacy business, including manufacturing/supply chain disruptions, access to/demand for prescription drugs, changes in reimbursement rates, and regulatory changes.

Future Outlook

SelectQuote, Inc. revised its fiscal year 2026 guidance, now expecting revenue in the range of $1.61 billion to $1.71 billion and Adjusted EBITDA between $90 million and $100 million. The company anticipates generating operating cash flow of $25 million to $35 million and Cash EBITDA of $60 million to $70 million for FY2026, driven by strong operational execution and improved balance sheet flexibility.

Management Comments

• "This year's AEP again highlighted the strength and consistency of SelectQuote's operating model."
• "Despite continued volatility in Medicare Advantage benefit structures, our team delivered another season of high-quality execution, with strong agent productivity and marketing efficiency driving 39% Adjusted EBITDA margins for our Senior business."
• "Our rapidly growing Healthcare Services segment, led by SelectRx, continues to provide meaningful clinical value for members and attractive long-term economics for our platform."
• "Our revised fiscal 2026 guidance reflects two discrete, partner-driven headwinds: a national carrier's decision to constrain additional MA policy volume by curtailing strategic marketing spend across all channels, and the previously communicated PBM reimbursement changes. Neither impact related to our internal performance, which remained strong."
• "While these developments are frustrating, they do not alter our conviction in the long-term earnings power of SelectQuote's comprehensive healthcare platform."
• "What continues to give us confidence is the consistency of our underlying operational execution. Regardless of the market backdrop, our teams have demonstrated the ability to drive efficiency, deliver value for partners and beneficiaries, and maintain strong margin discipline. Coupled with our improved balance sheet flexibility, we believe this operational consistency positions SelectQuote to deliver meaningful cashflow generation for shareholders in the quarters and years ahead."

Industry Context

StockSavvy.ai notes that the insurance brokerage industry, particularly in Medicare Advantage, faces ongoing volatility due to carrier benefit structure changes and marketing spend adjustments. SelectQuote's ability to maintain strong Senior segment margins and recapture customers despite these disruptions indicates resilience. The growth in Healthcare Services, especially SelectRx, aligns with a broader industry trend towards integrated healthcare solutions that address medication adherence and patient outcomes, offering a diversified revenue stream beyond traditional insurance sales.

Comparison to Industry Standards

• The 39% Adjusted EBITDA margin in the Senior segment is a strong indicator of operational efficiency, potentially outperforming some competitors in a volatile Medicare Advantage market.
• The 17% growth in SelectRx members and 26% revenue growth in Healthcare Services suggest SelectQuote is effectively capitalizing on the growing demand for integrated pharmacy and chronic care management services, a trend seen across the healthcare sector with companies like CVS Health (Aetna) and UnitedHealth Group (Optum) expanding their service offerings.
• The decrease in Lifetime Value (LTV) per approved MA policy to $874, while a negative, reflects broader industry pressures on commission structures and policy persistency, which many insurance brokers are navigating.
• The successful debt refinancing to extend maturities to 2031 provides a more stable capital structure compared to companies facing near-term debt walls, enhancing long-term financial flexibility.

Legal Proceedings

• Potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act.

Stakeholder Impact

• Shareholders: Mixed impact due to strong Q2 revenue and net income but lowered full-year guidance and decreased Adjusted EBITDA. Debt refinancing provides long-term stability.
• Customers (Seniors): Positive impact from the high-touch model ensuring strong recapture rates despite carrier policy changes, and continued clinical value from SelectRx.
• Employees (Agents): Strong agent productivity highlighted, suggesting stable or improving operational environment for sales force.
• Insurance Carrier Partners: Impacted by a national carrier's decision to curtail MA policy volume, indicating potential shifts in partner relationships.
• Pharmacy Benefit Managers (PBMs): Impacted by previously communicated reimbursement changes, though a new multiyear agreement provides predictability.
• Creditors: Positive impact from debt refinancing, extending maturities to 2031 and improving balance sheet flexibility.

Next Steps

• Continue to drive efficiency and maintain strong margin discipline across segments.
• Focus on delivering meaningful cash flow generation for shareholders.
• Leverage improved balance sheet flexibility for growth optionality.
• Continue to grow SelectRx membership and provide clinical value.
• Manage impacts from partner-driven headwinds in MA policy volume and PBM reimbursement changes.

Key Dates

Recommendation

The company demonstrated strong operational execution in its core Senior segment and robust growth in Healthcare Services revenue during Q2. However, the significant downward revision of full-year revenue and Adjusted EBITDA guidance, attributed to external partner-driven headwinds, introduces considerable uncertainty regarding future profitability. While the debt refinancing improves capital structure, the reduced outlook warrants a cautious 'hold' stance until there is clearer visibility on the stabilization of carrier relationships and PBM reimbursement rates, and a sustained positive trend in Adjusted EBITDA.

Keywords

SelectQuote, SLQT, Medicare Advantage, Healthcare Services, SelectRx, Insurance Broker, Financial Results, Q2 Earnings, Fiscal Year 2026, Guidance Revision, Debt Refinancing, PBM Reimbursement, Senior Insurance, Life Insurance